| pubmed-article:2920584 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2920584 | lifeskim:mentions | umls-concept:C0024117 | lld:lifeskim |
| pubmed-article:2920584 | lifeskim:mentions | umls-concept:C0025815 | lld:lifeskim |
| pubmed-article:2920584 | lifeskim:mentions | umls-concept:C0013969 | lld:lifeskim |
| pubmed-article:2920584 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:2920584 | lifeskim:mentions | umls-concept:C0282440 | lld:lifeskim |
| pubmed-article:2920584 | lifeskim:mentions | umls-concept:C1096777 | lld:lifeskim |
| pubmed-article:2920584 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2920584 | pubmed:dateCreated | 1989-4-12 | lld:pubmed |
| pubmed-article:2920584 | pubmed:abstractText | We conducted a randomized, controlled double-blind study to determine whether intravenous administration of methylprednisolone early in the therapy for acute exacerbations of COPD would improve pulmonary function in the Emergency Department and reduce the need for hospitalization. Ninety-six patients completed the study. All were at least 50 years of age and had no history of asthma. Patients received aminophylline and hourly administration of aerosolized isoetharine. Methylprednisolone (100 mg) or physiologic saline solution was given within one-half hour of arrival in the Emergency Department. Spirometry was performed initially and after the third and fifth aerosol treatments. We found no greater improvement in FEV1 in the group receiving the steroid (37 percent) than in the control group (43 percent; NS). There was also no difference in the rate of hospitalization (33 percent in the steroid-treated group vs 30 percent in the control group; NS). We conclude that early administration of methylprednisolone does not affect the emergency phase of treatment for acute exacerbations of COPD. | lld:pubmed |
| pubmed-article:2920584 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2920584 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2920584 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2920584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2920584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2920584 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2920584 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:2920584 | pubmed:issn | 0012-3692 | lld:pubmed |
| pubmed-article:2920584 | pubmed:author | pubmed-author:LukensT WTW | lld:pubmed |
| pubmed-article:2920584 | pubmed:author | pubmed-author:BAHH | lld:pubmed |
| pubmed-article:2920584 | pubmed:author | pubmed-author:EmermanC LCL | lld:pubmed |
| pubmed-article:2920584 | pubmed:author | pubmed-author:EffronDD | lld:pubmed |
| pubmed-article:2920584 | pubmed:author | pubmed-author:ConnorsA FAF | lld:pubmed |
| pubmed-article:2920584 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2920584 | pubmed:volume | 95 | lld:pubmed |
| pubmed-article:2920584 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2920584 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2920584 | pubmed:pagination | 563-7 | lld:pubmed |
| pubmed-article:2920584 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:meshHeading | pubmed-meshheading:2920584-... | lld:pubmed |
| pubmed-article:2920584 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2920584 | pubmed:articleTitle | A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. | lld:pubmed |
| pubmed-article:2920584 | pubmed:affiliation | Department of Emergency Medicine, Cleveland Metropolitan General Hospital, Ohio. | lld:pubmed |
| pubmed-article:2920584 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2920584 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2920584 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2920584 | lld:pubmed |
